Table of Contents

Obesity and its related conditions remain a pressing issue in the US. The World Obesity Federation’s 2023 Atlas projects that within the next 12 years, more than 4 billion people, about 51% of the world’s population, will be living with overweight or obesity.

Weight loss remains one of the most effective ways to address obesity. Even a modest reduction of 5-10% of body weight can improve heart health and lower blood sugar levels. Treatment options range from nutrition and physical activity to behavioral therapy, prescription medications, and, in some cases, bariatric surgery.

Medications that act on hormones controlling hunger and calorie use have changed how obesity is treated. New drugs such as tirzepatide and emerging candidates like retatrutide promise significant weight loss, but patients understandably wonder how they differ.

This article explores the science, clinical results, safety profiles, and practical considerations of these two medications to help you make informed decisions.

Key Takeaways

  • Retatrutide activates GLP-1, GIP, and glucagon receptors, leading to 28.7% weight loss at 68 weeks and improvements in blood pressure, glucose, and lipids.
  • Tirzepatide activates GIP and GLP-1 receptors and is FDA-approved for diabetes (Mounjaro) and weight management (Zepbound). It achieved 22.5% weight loss at 72 weeks in the SURMOUNT-1 trial.
  • Cross-trial comparisons suggest that retatrutide may produce slightly greater and faster weight loss than tirzepatide, but no head-to-head data exist yet, and retatrutide’s long-term safety remains unknown.
  • Both drugs cause gastrointestinal side effects.
  • Tirzepatide can cost up to $1,086 per month without insurance, while retatrutide has no official price yet.
  • Tirzepatide is FDA-approved, while retatrutide remains investigational. Avoid unapproved products and discuss options with your healthcare provider.

Understanding retatrutide

Before we put retatrutide head-to-head with tirzepatide, let’s first understand how it works and what makes it different from current weight loss medications.

How does retatrutide work?

Retatrutide (LY3437943), often called “Triple G,” targets three hormone receptors:

    • Glucagon-like peptide-1 (GLP-1) receptor
    • Glucose-dependent insulinotropic polypeptide (GIP) receptor
    • Glucagon receptor

Each of these hormones contribute in appetite regulation and energy metabolism. GLP-1 and GIP slow stomach emptying and increase the feeling of fullness, while glucagon prompts the liver to break down stored energy and may boost energy expenditure.

A correspondence article published in Health Science Reports explains that retatrutide is about 30% as potent as natural glucagon, about 40% as potent as natural GLP-1, and about 8.9 times more potent than natural GIP.

How much weight can you lose on retatrutide?

Retatrutide’s promise comes from a double-blind, placebo-controlled phase 2 trial involving 338 adults with obesity or overweight. Participants were randomly assigned to receive different doses of retatrutide or placebo for 11 months.

The trial showed that weight loss was dose-dependent. The mean percentage weight reductions were as follows:

Dose Group

 Starting Dose Strategy Mean % Weight Change (Week 24)

Mean % Weight Change (Week 48)

1 mg

 – 7.2%

8.7%

4 mg

 Started at 2 mg 11.8%

16.3%

4 mg

 Started at 4 mg 13.9%

17.8%

8 mg

 Started at 2 mg 16.7%

21.7%

8 mg

 Started at 4 mg 17.9%

23.9%

12 mg

 Started at 2 mg 17.5%

24.2%

Placebo

 – 1.6%

2.1%

Notably, 26% of participants in the 12-mg group lost at least 30% of their baseline weight.

More recently, TRIUMPH 4 was a large phase 3 clinical trial testing retatrutide in adults who:

    • had obesity or overweight
    • also had knee osteoarthritis
    • did not have diabetes

About 84% had a BMI of 35 or higher, and the average starting weight was 112.7 kg, or about 248 lbs.

At the highest dose, 12 mg, people lost an average of 28.7% of their body weight, which is about 71 lbs. For comparison, those on the 9 mg dose had a 26.4% weight loss, and those on the placebo had a 2.1% weight loss.

More impressively:

    • 58.6% of people on 12 mg lost at least 25% of their body weight
    • 39.4% lost at least 30%
    • Nearly 1 in 4 lost 35% or more

These numbers are higher than what we typically see with currently approved GLP-1-based drugs.

Other potential benefits of retatrutide

Beyond weight loss, retatrutide improved several cardiometabolic measures:

    • Approximately 72% of participants with prediabetes achieved normal HbA1c levels (<5.7%) at week 48, compared with 22% in the placebo group.
    • Up to 19.6 cm reduction in waist circumference, the placebo group reduced only 2.6 cm.

In TRIUMPH 4, researchers also measured pain using the WOMAC pain score, a standard tool for osteoarthritis. The 12 mg dose resulted in about a 75% reduction in pain. About 1 in 8 patients on retatrutide were completely free of knee pain by the end of the trial. Around 68% to 73% achieved at least a 70% reduction in pain, compared with 26% on placebo.

Participants also improved in mobility and daily function. On 12 mg, physical function scores improved by about 74%, while the placebo improved by about 36%.

Side effects of retatrutide

The most common side effects were mild-to-moderate gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. Some participants experienced supraventricular arrhythmias and cardiac conduction disorders, but these events were rare.

Serious adverse events occurred in 13 people, but the rate was similar to that of the placebo group, which suggests no overall increase in serious safety events.

Only 1% of participants had a temporary rise in ALT (a liver enzyme) above three times the normal limit. By week 48, average ALT and AST levels were stable or even lower. There was no indication of ongoing liver injury during the study period.

Has retatrutide been approved by the FDA?

As of this writing (February 2026), retatrutide is still an investigational drug. Seven more phase 3 trials of retatrutide in obesity and type 2 diabetes are expected to finish in 2026. These studies will help determine:

    • Long-term safety
    • Broader effectiveness
    • Potential FDA approval timing

The FDA has issued warnings to companies illegally selling unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are misleadingly labeled “for research purposes” or “not for human consumption.” Despite these labels, some of these products have been marketed directly to consumers with dosing instructions for human use.

The agency advises consumers not to purchase these products, as their quality, safety, and ingredients are unknown and they may pose serious health risks.

Retatrutide vs. tirzepatide for weight loss

Retatrutide vs tirzepatide for weight loss

Retatrutide and tirzepatide have never been compared head-to-head in a single trial, so any comparisons rely on separate studies with different populations and durations. Nevertheless, the available data suggest that retatrutide may induce greater average weight loss than tirzepatide:

    • Retatrutide (Triple G) – In the TRIUMPH 4 trial, participants lost an average of 28.7% of body weight at 68 weeks at the 12 mg dose. Plus, 58.6% of people on 12 mg lost at least 25% of their body weight.
    • Tirzepatide (Zepbound) – In the SURMOUNT 1 trial, participants lost an average of 22.5% of body weight at 72 weeks at the15 mg dose. About 57% of people on 15 mg achieved at least 20% weight loss.

In phase 2 and 3 studies of other weekly GLP-1 receptor agonists, the reported weight loss has generally been lower:

    • Dulaglutide 4.5 mg led to about 5% weight loss
    • Semaglutide 2 mg led to about 7.2% weight loss
    • Semaglutide 2.4 mg led to about 15.2% weight loss

These numbers suggest that triple receptor agonists like retatrutide may have a higher maximum weight loss potential than dual agonists. In phase 2 trials, retatrutide also produced a 17.5% reduction in body weight within 24 weeks, reaching clinically meaningful milestones faster.

However, cross-trial comparisons have limitations. Participants differed in baseline weight, comorbidities, diet and lifestyle counselling, and adherence. The only way to truly determine which drug performs best would be a direct head-to-head clinical trial under identical conditions.

More importantly, retatrutide is still under investigation, and long-term data beyond 68 weeks are lacking. Until then, we cannot determine with certainty which drug delivers the best overall results.

Heart and metabolic considerations

Because retatrutide activates the glucagon receptor, which can raise heart rate, clinicians monitor cardiovascular parameters. In the phase 2 trial, heart-rate increases were dose dependent, peaking early and then declining.

A small number of participants experienced supraventricular arrhythmias or conduction disturbances, but serious events were rare and similar between retatrutide and placebo.

Tirzepatide does not significantly increase heart rate.

Dosing, administration, and convenience

Both retatrutide and tirzepatide are administered as subcutaneous injections. Retatrutide’s long half-life allows once-weekly dosing. Studies showed that the drug’s half-life is nearly six days, permitting weekly injections with steady blood levels.

Tirzepatide is also injected weekly, with doses ranging from 2.5 mg to 15 mg. Patients typically start at 2.5 mg and titrate up every four weeks to minimize side effects. Pens are pre-filled and easy to use, while vials require syringes. You will also be trained on proper injection technique and how to rotate your injection sites correctly.

Neither medication is intended for daily use. But because retatrutide is still investigational, dosing schedules may change once phase 3 data are available.

Cost and accessibility

The list price of Zepbound is $1,086.37 per fill, but costs vary widely. Patients with commercial insurance and a Zepbound savings card may pay as little as $25 per month. Without insurance, prices through LillyDirect’s self-pay program are $349 for the 2.5 mg vial and $499 for higher-dose vials.

There is no official price for retatrutide because it has not yet received FDA approval.

Zepbound coupons and discounts

Starts from $499.97

Have a prescription?

Choose Pharma Giant for affordable medications and take control of your health with reliable, cost-effective options today!

SAVE 10% with coupon code:

Bottom line

Tirzepatide has undergone rigorous phase 3 trials and is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Meanwhile, Retatrutide is still in the midst of phase 3 TRIUMPH trials evaluating its efficacy for obesity, obstructive sleep apnea, type 2 diabetes, and osteoarthritis.

Additional studies will also examine cardiovascular outcomes and compare retatrutide with existing treatments. These trials will determine whether triple agonist therapy delivers sustained benefits and how its safety profile evolves over time.

The FDA has not approved retatrutide, and the agency explicitly warns consumers about unapproved versions. Until results from phase 3 trials are published and the FDA completes a review, clinicians cannot prescribe retatrutide outside of clinical research.

Related Articles

Frequently Asked Questions

Current data suggest retatrutide may deliver slightly greater weight loss than tirzepatide. Phase 3 trials of retatrutide reported up to 28.7% weight loss at 68 weeks, while the SURMOUNT-1 trial for tirzepatide showed 22.5% weight loss at 72 weeks. However, the drugs have not been compared directly, and retatrutide is still investigational.

Switching medications should always be done under medical supervision. Retatrutide is not yet FDA-approved and is available only in clinical trials. Without approval, your provider cannot prescribe it outside of research. If retatrutide becomes approved, decisions about switching will depend on individual response, tolerability, and your insurance coverage.

In clinical trials, participants began losing weight within the first few weeks. Mean weight reductions reached 7-18 % by week 24, depending on dose. Because retatrutide is given once weekly and has a six-day half-life, effects build gradually. Gastrointestinal side effects, if they occur, usually appear during dose escalation and subside over time.

Among FDA-approved drugs, tirzepatide (Zepbound) produces the highest average weight loss (up to 22.5% at 72 weeks). Retatrutide, which also activates the glucagon receptor, showed 24.2% weight loss at 48 weeks in phase 2 trials but is not yet approved. Future head-to-head trials will clarify which therapy is strongest.

Based on current approvals, tirzepatide (Zepbound) is the most effective weight-loss drug available, with patients losing about 22.5% of their body weight. Retatrutide may eventually surpass it, but only if phase 3 trials confirm its effectiveness and safety. The choice of drug also depends on individual health conditions and insurance coverage.

No. Ozempic is a brand of semaglutide, a single GLP-1 receptor agonist. Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors. Semaglutide is FDA-approved for diabetes and weight management (as Wegovy), while retatrutide remains in clinical trials.

Not yet. Retatrutide is currently being tested in phase 3 trials and has no FDA approval. The FDA warns consumers to avoid unapproved versions of GLP-1 drugs, including retatrutide, because their safety and effectiveness have not been reviewed.

Retatrutide commonly causes mild gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. Clinical trials noted a dose-related increase in heart rate and rare supraventricular arrhythmias. Long-term risks are unknown because the drug is still investigational.

Retatrutide includes GLP-1 receptor activation but also stimulates GIP and glucagon receptors. In vitro studies show that its potency at the GIP receptor is nearly nine times greater than natural GIP, while its GLP-1 and glucagon receptor activity is lower than that of the natural hormones.

Because retatrutide is not yet on the market, no official price exists.

Retatrutide is being studied for chronic weight management and type 2 diabetes. Phase 3 trials are also exploring its use for obesity-related conditions such as sleep apnea and osteoarthritis. But it is not yet approved for any use.

No. Retatrutide is designed as a once-weekly injection. It has a half-life of approximately six days, which maintains drug levels throughout the week. Daily administration has not been studied and is not recommended.

Laboratory studies indicate that multi-agonist peptides, including retatrutide, may provide neuroprotective and anti-inflammatory effects in cell culture models. However, these large peptides have limited ability to cross the blood-brain barrier, and no clinical trials have evaluated retatrutide for cognitive disorders. Any claims about improved memory or anti-aging effects are speculative.

There is no scientific evidence that retatrutide reverses aging. The drug is being developed to treat obesity and metabolic disorders. While laboratory research hints at anti-inflammatory effects, no human studies have linked retatrutide to anti-aging benefits.

In the phase 2 obesity trial, retatrutide increased heart rate in a dose-dependent manner and caused occasional supraventricular arrhythmias, but serious cardiac events were rare and comparable to placebo. The drug also improved blood pressure and lipids. Long-term cardiovascular outcomes are under investigation in ongoing trials.

Sources

Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

FDA. (2026, February 4). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food And Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., Wharton, S., & Group, T. S. 5. S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Naeem, M., Imran, L., & Banatwala, U. E. S. S. (2024). Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Science Reports, 7(2), e1864. https://doi.org/10.1002/hsr2.1864

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/nejmoa2301972

Abouelmagd, A. A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Baylor University Medical Center Proceedings, 38(3), 291–303. https://doi.org/10.1080/08998280.2025.2456441

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038

Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., Pirro, V., Wainscott, D. B., Willard, F. S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R. E., Haupt, A., & Milicevic, Z. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013

Giblin, K., Kaplan, L. M., Somers, V. K., Roux, C. W. L., Hunter, D. J., Wu, Q., Lalonde, A., Ahmad, N., & Bethel, M. A. (2025). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obesity and Metabolism, 28(1), 83–93. https://doi.org/10.1111/dom.70209

Kopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024). Incretin-Based Multi-Agonist peptides are neuroprotective and Anti-Inflammatory in cellular models of neurodegeneration. Biomolecules, 14(7), 872. https://doi.org/10.3390/biom14070872